Cascade impactor practice for a high dose dry powder inhaler at 90 L/min: NGI versus modified 6-stage and 8-stage ACI

Journal of Pharmaceutical Sciences

Volumn 98, Issue 3, 2009, Pages 1028-1039

  Kamiya, Akihiko ^a,b   Sakagami, Masahiro ^a   Byron, Peter R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aerodynamic diameter; Aerosols; Bioequivalence; Cascade impactor; Dry powder inhaler; Formulation; Particle size; Regulatory science; Silicone coating; USP

Indexed keywords

SILICONE; ZANAMIVIR;

ACCURACY; ARTICLE; DRUG DELIVERY SYSTEM; INTERMETHOD COMPARISON; PARTICLE SIZE; POWDER INHALER;

EID: 62849094735     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21501     Document Type: Article

References (22)

1. United States Pharmacopeial Convention. 2007. General Chapter 〈601〉 Aerosols, metered-dose inhalers, and dry powder inhalers. In: USP30-NF25, Rockville, MD, p 220-240.
2. European Pharmacopoeia. 2002. Section 2.9.18 Preparations for inhalation: Aerodynamic assessment of fine particles. In: EP (3rd Ed.) Strasboarg, France, p 113-124.
3. Clark AR, Kadrichu N. 2000. Comparing pharmaceutical aerosol particle size distributions: How do we judge similarity? In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery VII. North Carolina: Serentec Press. pp 145-154.
4. Byron PR. 2002. In vitro bioequivalence of particle size distributions: A commentary on FDA's draft guidance. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery VIII. North Carolina: David Horwood International Publishing, Ltd. pp 145-154.
5. Adams WP, Christopher D, Lee DS, Morgan B, Pan Z, Singh GJ, Tsong Y, Lyapustina S. 2007. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 1: Background for statistical methods. AAPS PharmSciTech 8:4.
6. Christopher D, Adams WP, Lee DS, Morgan B, Pan Z, Singh GJ, Tsong Y, Lyapustina S. 2007. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 2: Evaluation of a method for determining equivalence. AAPS PharmSciTech 8:5.
7. Marple VA, Roberts DL, Romay FJ, Miller NC, Truman KG, Van Oort M, Olsson B, Holroyd MJ, Mitchell JP, Hochrainer D. 2003. Next generation pharmaceutical impactor (a new impactor for pharmaceutical aerosol testing). Part I: Design. J Aerosol Med 16:283-299.
8. Marple VA, Olson BA, Kumaragovindham S, Mitchell JP, Murray SC, Hudson-Curtis BL. 2003. Next generation pharmaceutical impactor (a new impactor for pharmaceutical aerosol testing). Part II: Archival calibration. J Aerosol Med 16:301-324.
9. Stein SW, Olson BA. 1997. Variability in size distribution measurements obtained using multiple Andersen Mark II cascade impactors. Pharm Res 14:1718-1725.
10. Marple VA, Olson BA, Miller NC. 1998. The role of inertial particle collectors in evaluating pharmaceutical aerosol delivery systems. J Aerosol Med 11:S139-S153.
11. Mitchell JP, Costa PA, Waters S. 1998. An assessment of an Andersen Mark-II cascade impactor. J Aerosol Sci 19:213-231.
12. Nichols SC. 2000. Calibration and mensuration issues for the standard and modified Andersen cascade impactor. Pharmacopeial Forum 26:1466-1469.
13. Vaughan NP. 1989. The Andersen impactor: Calibration, wall losses and numerical simulation. J Aerosol Sci 20:67-90.
14. Relenza® Rotadisk® (zanavimir for inhalation) with the Diskhaler® inhalation device, Prescription information, GlaxoSmithKline, Research Triangle Park, NC, available at http://us.gsk.com/products/assets/us- relenza.pdf.
15. Kamiya A, Sakagami M, Hindle M, Byron PR. 2004. Aerodynamic sizing of metered dose inhales: An evaluation of the Andersen and Next Generation Pharmaceutical Impactors and their USP methods. J Pharm Sci 93:1828-1837.
16. Hindle M, Byron PR, Miller NC. 1996. Cascade impactor methods for dry powder inhalers using the high flow rate Marple-Miller Impactor. Int J Pharm 134:137-146.
17. Weda M, Zanen P, de Boer AH, Gjaltema D, Ajaoud A, Barends DM, Frijlink HW. 2002. Equivalence testing of salbutamol dry powder inhalers: In vitro impaction results versus in vivo efficiency. Int J Pharm 249:247-255.
18. Christopher D, Curry P, Doub B, Furnkranz K, Lavery M, Lin K, Lyapustina S, Mitchell JP, Rogers B, Strickland H, Tougas T, Tsong Y, Wyka B. 2003. Considerations for the development and practice of cascade impaction testing, including a mass balance failure investigation tree. J Aerosol Med 16:235-247.
19. Miller NC, Ross DL, Nasr MM. 1998. Effect of formulation factors on the observed bounce in cascade impactors used to measure the spray particle size of metered dose inhalers. Int J Pharm 173:93-102.
20. Dunbar C, Kataya A, Tiangbe T. 2005. Reducing bounce effects in the Andersen cascade impactor. Int J Pharm 301:25-32.
21. Cass LM, Brown J, Pickford M, Fayinka S, Newman SP, Johansson CJ, Bye A. 1999. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 36:21-31.
22. Hübner M, Hochhaus G, Derendorf H. 2005. Comparable pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin N Am 25:469-488.